Cargando…

Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients

The safety and efficacy of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) emergency-use authorized (EUA) vaccines have been confirmed in the general population. However, there are no data on its safety and tolerability or efficacy in recipients of allogeneic hematopoietic stem cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Haris, Ngo, Dat, Aribi, Ahmed, Arslan, Shukaib, Dadwal, Sanjeet, Marcucci, Guido, Nakamura, Ryotaro, Forman, Stephen J., Chen, Jason, Al Malki, Monzr M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. 2021
Materias:	Full Length Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280601/ https://www.ncbi.nlm.nih.gov/pubmed/34274492 http://dx.doi.org/10.1016/j.jtct.2021.07.008

Ejemplares similares

The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study
por: Ngo, Dat, et al.
Publicado: (2023)

Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience
por: Amanam, Idoroenyi, et al.
Publicado: (2023)

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience
por: Amanam, Idoroenyi, et al.
Publicado: (2021)

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study
por: La Rosa, Corinna, et al.
Publicado: (2023)

Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation
por: Mascarenhas, Kristen, et al.
Publicado: (2019)

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens
por: Yao, Janny M., et al.
Publicado: (2022)

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
por: Aldoss, Ibrahim, et al.
Publicado: (2017)

Haploidentical hematopoietic cell transplant recipient presents with late‐onset Epstein Barr virus‐associated posttransplant lymphoproliferative disorder
por: Braun, Adam, et al.
Publicado: (2023)

Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation
por: Malki, Monzr M. Al, et al.
Publicado: (2019)

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

Late‐occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors
por: Sy, Andrew, et al.
Publicado: (2021)

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients
por: Aldoss, Ibrahim, et al.
Publicado: (2018)

Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Chang, Ellen K., et al.
Publicado: (2021)

Frequently Asked Questions about Mpox (Formerly Monkeypox Disease) for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Recipients from the American Society for Transplantation and Cellular Therapy
por: Ford, Emily S., et al.
Publicado: (2023)

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients
por: Waghmare, Alpana, et al.
Publicado: (2020)

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
por: Golan, Yoav, et al.
Publicado: (2021)

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study
por: Ali, Haris, et al.
Publicado: (2022)

Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity
por: Pourhassan, Hoda, et al.
Publicado: (2022)

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Ariza-Heredia, Ella J, et al.
Publicado: (2023)

Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal
por: Valentini, Caterina Giovanna, et al.
Publicado: (2021)

Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
por: Huang, Alice, et al.
Publicado: (2022)

Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation
por: Kum, Elena, et al.
Publicado: (2021)

Cutaneous Legionella infections in allogeneic hematopoietic cell transplantation recipients
por: Vaidya, Toral, et al.
Publicado: (2020)

Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients
por: Yew, P Y, et al.
Publicado: (2015)

Putative Protective Role of Sars-Cov-2-Specific T Cells in an HCT Patient Transplanted during Active COVID19 Infection
por: Pourhassan, Hoda, et al.
Publicado: (2022)

Role of radiotherapy in treatment of extramedullary relapse following total marrow and lymphoid irradiation in high-risk and/or relapsed/refractory acute leukemia
por: Ladbury, Colton, et al.
Publicado: (2022)

Treatment of allosensitized patients receiving allogeneic transplantation
por: Ciurea, Stefan O., et al.
Publicado: (2021)

Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report
por: Bankova, Andriyana K., et al.
Publicado: (2022)

1760. Outcomes of Acyclovir-Resistant Herpes Simplex Virus Infections in Hematologic Malignancies and Hematopoietic Cell Transplant
por: Ross, Justine Abella, et al.
Publicado: (2019)

Toxoplasma Encephalitis in an Allogeneic Hematopoietic Stem Cell Transplant Recipient in Korea
por: Park, Soo-Kyung, et al.
Publicado: (2012)

Assessment of oral health condition in recipients of allogeneic hematopoietic cell transplantation
por: Reis, Thiago de Carvalho, et al.
Publicado: (2022)

Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
por: Dioverti, Veronica, et al.
Publicado: (2022)

Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients
por: Kimura, Muneyoshi, et al.
Publicado: (2022)

Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation
por: Lin, Ren, et al.
Publicado: (2013)

Acinetobacter baumannii Septicemia in a Recipient of an Allogeneic Hematopoietic Stem Cell Transplantation
por: Al-Anazi, Khalid Ahmed, et al.
Publicado: (2012)

Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Stern, Lauren, et al.
Publicado: (2019)

Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation
por: DeFilipp, Zachariah, et al.
Publicado: (2019)

Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients
por: Lahtinen, Atte K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1epmenjneid07uaiqtk4v1ivsc